Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0YX7E
|
|||
Former ID |
DCL000584
|
|||
Drug Name |
Ortataxel
|
|||
Synonyms |
UNII-8H61Y4E29N; 186348-23-2; 8H61Y4E29N; IDN-5109; IDN 5109; Ortataxel [INN]; Bay-59-8862; SB-T-101131; SB-T 101131; idn5109; SCHEMBL9932772; CHEMBL382300; BAY-59; IND-5109; DB11669; Z-3102; Hexanoic acid, 3-(((1,1-dimethylethoxy)carbonyl)amino)-2-hydroxy-5-methyl-,; Hexanoic acid; IND5109; 13-(N-tert-butoxycarbonyl-beta-isobutyisoserinyl)-14-hydroxy-baccatin-1,14-carbonate; 13-(N-tert-butoxycarbonyl-beta-isobutyisoserinyl)-14-hydroxybaccatin-1,14-carbonate; Genz29155
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 2 | [1] | |
Heart transplant rejection [ICD-11: NE84; ICD-9: 996] | Preclinical | [2] | ||
Company |
Spectrum
|
|||
Structure |
Download2D MOL |
|||
Formula |
C44H57NO17
|
|||
Canonical SMILES |
CC1=C2C(C(=O)C3(C(CC4C(C3C(C5(C2(C)C)C(C1OC(=O)C(C(CC(C)C)NC(=O)OC(C)(C)C)O)OC(=O)O5)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)OC(=O)C
|
|||
InChI |
1S/C44H57NO17/c1-20(2)17-25(45-38(53)61-40(6,7)8)29(49)37(52)57-30-21(3)28-31(56-22(4)46)33(50)42(11)26(48)18-27-43(19-55-27,60-23(5)47)32(42)35(58-36(51)24-15-13-12-14-16-24)44(41(28,9)10)34(30)59-39(54)62-44/h12-16,20,25-27,29-32,34-35,48-49H,17-19H2,1-11H3,(H,45,53)/t25-,26-,27+,29+,30+,31+,32-,34-,35-,42+,43-,44+/m0/s1
|
|||
InChIKey |
BWKDAMBGCPRVPI-ZQRPHVBESA-N
|
|||
CAS Number |
CAS 186348-23-2
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
References | Top | |||
---|---|---|---|---|
REF 1 | Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and tRA96023. Cancer Chemother Pharmacol. 2004 May;53(5):363-9. | |||
REF 2 | New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21. | |||
REF 3 | Clinical pipeline report, company report or official report of Spectrum Phamaceuticals (2009). | |||
REF 4 | Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours. Br J Cancer. 2008 Nov 18;99(10):1579-85. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.